| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Cerebrolysin je látka s neurotrofickým a neuroprotektivním účinkem. Vyrábí se enzymatickou degradací purifikovaných mozkový proteinů a skládá se z nízkomekulárních peptidů a aminokyselin. Celulární a animální modely mozkové ischemie ukázaly, že má významný neuroprotektivní účinek. Provedli jsme randomizovanou, placebem kontrolovanou studii v níž nemocní s akutním iktem byli randomizováni do 24 hodin na terapii placebem nebo Cerebrolysinem 50 ml/den po dobu 21 dnů. V obou skupinách se podávala též ASA a pentoxyphyllin. Hodnocení provedeno kanadskou neurologickou škálou, indexem Bartelové a CGI. Výsledky: 146 nemocných ve dvou skupinách, pacienti na Cerebrolysinu neměli žádné signifikantní zlepšení proti placebu ve skore CNS, BI a CGI. Signifikantní zlepšeni kognitivních funkcí na Cerebrolysinu bylo pozorováno v Syndrome Short Test. Cerebrolisyn byl dobře tolerován a bezpečný. (cs)
- Cerebrolysin is a compound with neurotrophic and neuroprotective activity. It is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids. Cellular and animal models of cerebral ischaemia have shown that it is a potent neuroprotective agent. We explored the safety and preliminary outcome of Cerebrolysin treatment in patients with acute stroke. Methods. Randomised, placebo-controlled, parallel group trial. Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days. Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV. Clinical examinations were performed on days 1, 3, 7, 21 and 90 post baseline. Outcome measures were the Canadian Neurological Scale, the Barthel Index, the Clinical Global Impressions, the Mini-Mental State Examination, and the Syndrome Short Test. Treatment emergent adverse events, lab tests, and vital
- Cerebrolysin is a compound with neurotrophic and neuroprotective activity. It is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids. Cellular and animal models of cerebral ischaemia have shown that it is a potent neuroprotective agent. We explored the safety and preliminary outcome of Cerebrolysin treatment in patients with acute stroke. Methods. Randomised, placebo-controlled, parallel group trial. Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days. Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV. Clinical examinations were performed on days 1, 3, 7, 21 and 90 post baseline. Outcome measures were the Canadian Neurological Scale, the Barthel Index, the Clinical Global Impressions, the Mini-Mental State Examination, and the Syndrome Short Test. Treatment emergent adverse events, lab tests, and vital (en)
|
| Title
| - Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial
- Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial (en)
- Neuroprotektivní léčba Cerebrolysinem u pacientů s akutním iktem: randomisovaná a kontrolovaná studie (cs)
|
| skos:prefLabel
| - Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial
- Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial (en)
- Neuroprotektivní léčba Cerebrolysinem u pacientů s akutním iktem: randomisovaná a kontrolovaná studie (cs)
|
| skos:notation
| - RIV/00216208:11120/05:00001075!RIV09-MSM-11120___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/05:00001075
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - acute stroke; neuroprotection; clinical trial; stroke therapy; Cerebrolysin (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Journal of Neural Transmission
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Kalvach, Pavel
- Ladurner, G.
- Moessler, H.
|
| http://linked.open...ain/vavai/riv/wos
| |
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)